Reduced doses of anti-TNF — Competitive Intelligence Brief

Reduced doses of anti-TNF (Reduced doses of anti-TNF) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF inhibitor. Area: Immunology.

marketed TNF inhibitor TNF-α (Tumor Necrosis Factor-alpha) Immunology Small molecule

Target snapshot

Reduced doses of anti-TNF (Reduced doses of anti-TNF) — Spanish Clinical Pharmacology Society. Reduced doses of anti-TNF agents lower the concentration of tumor necrosis factor inhibitors to minimize immunosuppression while maintaining therapeutic benefit.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Reduced doses of anti-TNF TARGET	Reduced doses of anti-TNF	Spanish Clinical Pharmacology Society	marketed	TNF inhibitor	TNF-α (Tumor Necrosis Factor-alpha)
ETN+MTX	ETN+MTX	Japan Biological Agent Study Integrated Consortium	marketed	TNF inhibitor + DMARD combination	TNF-α receptor; dihydrofolate reductase
Etanercept via Autoinjector A	Etanercept via Autoinjector A	Amgen	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-α and TNF-β
Etanercept + Acitretin	Etanercept + Acitretin	Pfizer	marketed	TNF inhibitor + retinoid combination	TNF-α receptor (p75/p55) + retinoid X receptor (RXR) and retinoic acid receptor (RAR)
Etanercept via Autoinjector B	Etanercept via Autoinjector B	Amgen	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-α and TNF-β
Enbrel (etanercept)	Enbrel (etanercept)	Pfizer	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-alpha (TNF) and TNF-beta (lymphotoxin-alpha)
Standard dose of TNFi	Standard dose of TNFi	University Health Network, Toronto	marketed	TNF inhibitor	TNF-α (tumor necrosis factor-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF inhibitor class)

1. University Hospital, Montpellier · 2 drugs in this class
2. Amgen · 1 drug in this class
3. Biogen · 1 drug in this class
4. Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class
5. National Eye Institute (NEI) · 1 drug in this class
6. Abbott · 1 drug in this class
7. Spanish Clinical Pharmacology Society · 1 drug in this class
8. Takeda · 1 drug in this class
9. University Health Network, Toronto · 1 drug in this class
10. University Hospital, Ghent · 1 drug in this class